Skip to main content

Advertisement

Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study

Fig. 2

Adjusted survival curve based on Cox proportional hazard model. X axis represents days after bDMARD discontinuation. Y axis represents rates of maintained BFR. Survival curves adjusted for covariates based on Cox proportional hazard model. BFR biological disease-modifying antirheumatic drug-free remission, TNFi(mAb) monoclonal antibodies against TNF (infliximab, adalimumab, and golimumab), TNFi(R/P) soluble TNF receptor or Fab fragments against TNF fused with polyethylene glycol (etanercept and certolizumab), CTLA4-Ig abatacept, IL-6Ri interleukin-6 receptor inhibitor (tocilizumab), TNF tumor necrosis factor

Back to article page